Suchergebnisse - "Schmid, Peter"

PubPharm (13)

1

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Rugo, H. | Bardia, A. | Marmé, F. | +15

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):734. - PMID 37684406

2

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Rugo, H. | Bardia, A. | Marmé, F. | +13

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):732-735. - PMID 36446052

3

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Llombart-Cussac, A. | Pérez-García, J. | Bellet, M. | +52

ErratumIn: JAMA Oncol. 2021 Nov 1;7(11):1729. - PMID 34792545

4

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

5

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pérez-García, J. | Llombart-Cussac, A. | G Cortés, M. | +16

6

Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer : a cross-sectional study evaluating the relationships between disease and treatment stage

enthalten in: Health and quality of life outcomes | 2020

von Verrill, M. | Wardley, A. | Retzler, J. | +6

7

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Robertson, J. | Evans, A. | Henschen, S. | +24

8

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Modi, S. | Saura, C. | Yamashita, T. | +99

CommentIn: Cancer Discov. 2020 Feb;10(2):167. - PMID 31843763

9

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130) : updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Schmid, P. | Rugo, H. | Adams, S. | +13

CommentIn: Lancet Oncol. 2020 Jan;21(1):3-5. - PMID 31786122

10

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Bachelot, T. | Ciruelos, E. | Schneeweiss, A. | +111

CommentIn: Ann Oncol. 2019 May 1;30(5):665-667. - PMID 30888412